Zoetis Stock

Zoetis EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Zoetis (ZTS) as of Aug 11, 2026 is 13.57. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 14.39 — a change of -5.70% (lower).

EV/EBIT

13.57

YoY

-5.70%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Zoetis is 2026 13.57 . EV/EBIT (Enterprise Value to EBIT) of Zoetis was 2025 14.39 . It decreases by -5.70% lower compared to the previous year.

The Zoetis EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
31.49 base
Jan 1, 2020
34.86 base
Jan 1, 2021
41.41 base
Jan 1, 2022
23.36 base
Jan 1, 2023
29.59 base
Jan 1, 2024
21.67 base
Jan 1, 2025
15.35 base
Jan 1, 2026 (e)
8.02 base
YEARPRICE-TO-EBIT
2026 est 8.02
2025 15.35
2024 21.67
2023 29.59
2022 23.36
2021 41.41
2020 34.86
2019 31.49
2018 22.03
2017 20.48
2016 18.94
2015 22.17
2014 22.33
2013 19.93
2012 -
2011 -
2010 -
2009 -
Access this data via the Eulerpool API

Zoetis Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Zoetis's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Zoetis's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Zoetis's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Zoetis grows earnings faster than its peers.

Zoetis Stock analysis

What does Zoetis do? Zoetis Inc. is a leading company in the development and marketing of animal health technology and solutions. The company specializes in innovative products for animals such as dairy cattle, pigs, poultry, dogs, cats, and horses. Zoetis was founded in 1952 as a subsidiary of Pfizer and operated as Pfizer Animal Health. In 2013, the company was finally spun off from Pfizer and became Zoetis Inc. Zoetis focuses on the development, manufacturing, and marketing of products for livestock and pets, including vaccines, pharmaceuticals, biological therapies, and diagnostics. The company operates globally and has its headquarters in Parsippany, New Jersey. Zoetis' business model consists of various business segments divided into animal categories: cattle, pigs, poultry, pets, and horses. Each of these business segments offers specialized solutions for animal owners and veterinarians. In the cattle products segment, Zoetis offers products for dairy cows, beef cattle, and calves. They also provide a variety of prevention and treatment solutions for major animal health issues such as mastitis, reproductive disorders, and respiratory problems. In the swine segment, Zoetis offers prevention and treatment solutions for infectious diseases and parasite control. They also provide products for promoting swine health and weight gain. In the poultry segment, Zoetis offers solutions for the prevention and treatment of infectious diseases. The company's products aim to improve animal health, productivity, and efficiency. Zoetis also offers products for the pet segment, including vaccines, pharmaceuticals, and therapies for dogs, cats, and other pets. Here, the company also provides solutions for major health issues such as heart diseases, pain management, and parasite control. In the horse segment, Zoetis offers solutions for the prevention and treatment of diseases such as equine rhinopneumonia, worm infestations, and arthritis. They also provide products for promoting horse health and performance. Zoetis is known for a variety of innovative products used by animal owners and veterinarians worldwide. One example is ScourGuard® 4KC, a vaccine that protects calves from diarrheal diseases caused by common bacteria. This vaccine has already proven to be highly effective in controlling bowel diseases in calves. Zoetis has also developed and marketed the first FDA-approved product for pain management in dogs (Rimadyl®), as well as the first licensed product for the treatment of giardia in dogs (Panacur®). In summary, Zoetis, as a global leader in the animal health industry, puts innovation and quality at the forefront. With a wide range of products and solutions in various animal categories, Zoetis is a key player in the animal health industry. Zoetis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zoetis stock

EV/EBIT (Enterprise Value to EBIT) of Zoetis is 13.57 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Zoetis changed from 14.39 to 13.57, representing a -5.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Zoetis since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Zoetis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Zoetis

All Key Metrics — Zoetis